Patients with insomnia and subthreshold depression show marked worsening of insomnia after discontinuation of sleep promoting medication

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 35, Issue 7, 2011, Pages 1671-1676

  Wichniak, Adam ^a   Wierzbicka, Aleksandra ^a   Jernajczyk, Wojciech ^a  

^a INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Poland)

Author keywords

Actigraphy; Antidepressants; Depressive symptoms; Pharmacological treatment; Primary insomnia; Trazodone

Indexed keywords

TRAZODONE;

ACTIMETRY; ADULT; AGE DISTRIBUTION; ARTICLE; ATHENS INSOMNIA SCALE; BECK DEPRESSION INVENTORY; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DAYTIME SOMNOLENCE; DEPRESSION; DIZZINESS; DRUG DOSE REDUCTION; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GENERAL CONDITION DETERIORATION; HUMAN; INSOMNIA; LEED SLEEP EVALUATION QUESTIONNAIRE; MALE; NEUROPSYCHOLOGICAL TEST; OUTCOME ASSESSMENT; PERCEPTIVE THRESHOLD; SCORING SYSTEM; SHEEHAN DISABILITY SCALE; SIDE EFFECT; SLEEP TIME; TREATMENT DURATION;

ACTIGRAPHY; ADULT; AGED; DELAYED-ACTION PREPARATIONS; DYSTHYMIC DISORDER; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SLEEP; SLEEP INITIATION AND MAINTENANCE DISORDERS; TRAZODONE; TREATMENT OUTCOME;

EID: 79961128827     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2011.06.010     Document Type: Article

References (33)

1. Ancoli-Israel S., Richardson G.S., Mangano R.M., Jenkins L., Hall P., Jones W.S. Long-term use of sedative hypnotics in older patients with insomnia. Sleep Med 2005, 6:107-113.
2. Beck A.T., Ward C.H., Mendelson M., Mock J., Eerbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961, 4:561-571.
3. Borbely A.A., Mattmann P., Loepfe M., Strauch I., Lehmann D. Effect of benzodiazepine hypnotics on all-night sleep EEG spectra. Hum Neurobiol 1985, 4:189-194.
4. Dording C.M., Mischoulon D., Petersen T.J., Kornbluh R., Gordon J., Nierenberg A.A., et al. The pharmacologic management of SSRI-induced side effects: a survey of psychiatrists. Ann Clin Psychiatry 2002, 14:143-147.
5. Erman M., Guiraud A., Joish V.N., Lerner D. Zolpidem extended-release 12.5mg associated with improvements in work performance in a 6-month randomized, placebo-controlled trial. Sleep 2008, 31:1371-1378.
6. Friedmann P.D., Herman D.S., Freedman S., Lemon S.C., Ramsey S., Stein M.D. Treatment of sleep disturbance in alcohol recovery: a national survey of addiction medicine physicians. J Addict Dis 2003, 22:91-103.
7. Guy W. Clinical Global Impression 1976, ECDEU Assessment Manual for Psychopharmacology, revised, National Institute of Mental Health, Rockville, MD.
8. Hajak G. New paradigms in the pharmacological treatment of insomnia. Sleep Med 2006, 7:S20-S26.
9. Katz D.A., McHorney C.A. Clinical correlates of insomnia in patients with chronic illness. Arch Intern Med 1998, 158:1099-1107.
10. Krystal A.D., Erman M., Zammit G.K., Soubrane C., Roth T. Long-term efficacy and safety of zolpidem extended-release 12.5mg, administered 3 to 7 nights per week for 24weeks, in patients with chronic primary insomnia: a 6-month, randomized, double-blind, placebo-controlled, parallel-group, multicenter study. Sleep 2008, 31:79-90.
11. Landolt H.P., Finelli L.A., Roth C., Buck A., Achermann P., Borbely A.A. Zolpidem and sleep deprivation: different effect on EEG power spectra. J Sleep Res 2000, 9:175-183.
12. Leon A.C., Olfson M., Portera L., Farber L., Sheehan D.V. Assessing psychiatric impairment in primary care with the Sheehan Disability Scale. Int J Psychiatry Med 1997, 27:93-105.
13. Lichstein K.L., Stone K.C., Donaldson J., Nau S.D., Soeffing J.P., Murray D., et al. Actigraphy validation with insomnia. Sleep 2006, 29:232-239.
14. Mendelson W.B. A review of the evidence for the efficacy and safety of trazodone in insomnia. J Clin Psychiatry 2005, 66:469-476.
15. Montgomery I., Oswald I., Morgan K., Adam K. Trazodone enhances sleep in subjective quality but not in objective duration. Br J Clin Pharmacol 1983, 16:139-144.
16. Morin C.M., Colecchi C., Stone J., Sood R., Brink D. Behavioral and pharmacological therapies for late-life insomnia: a randomized controlled trial. JAMA 1999, 281:991-999.
17. Owens J.A., Rosen C.L., Mindell J.A., Kirchner H.L. Use of pharmacotherapy for insomnia in child psychiatry practice: a national survey. Sleep Med 2010, 11:692-700.
18. Parrott A.C., Hindmarch I. The Leeds Sleep Evaluation Questionnaire in psychopharmacological investigations - a review. Psychopharmacology (Berl) 1980, 71:173-179.
19. Pinto L.R., Alves R.C., Caixeta E., Fontenelle J.A., Bacellar A., Poyares D., et al. New guidelines for diagnosis and treatment of insomnia. Arq Neuropsiquiatr 2010, 68:666-675.
20. Riemann D., Spiegelhalder K., Feige B., Voderholzer U., Berger M., Perlis M., et al. The hyperarousal model of insomnia: a review of the concept and its evidence. Sleep Med Rev 2010, 14:19-31.
21. Roth T., Rogowski R., Hull S., Schwartz H., Koshorek G., Corser B., et al. Efficacy and safety of doxepin 1mg, 3mg, and 6mg in adults with primary insomnia. Sleep 2007, 30:1555-1561.
22. Saletu-Zyhlarz G.M., Abu-Bakr M.H., Anderer P., Gruber G., Mandl M., Strobl R., et al. Insomnia in depression: differences in objective and subjective sleep and awakening quality to normal controls and acute effects of trazodone. Prog Neuropsychopharmacol Biol Psychiatry 2002, 26:249-260.
23. Schmid D.A., Wichniak A., Uhr M., Ising M., Brunner H., Held K., et al. Changes of sleep architecture, spectral composition of sleep EEG, the nocturnal secretion of cortisol, ACTH, GH, prolactin, melatonin, ghrelin, and leptin, and the DEX-CRH test in depressed patients during treatment with mirtazapine. Neuropsychopharmacology 2006, 31:832-844.
24. Soldatos C.R., Dikeos D.G., Paparrigopoulos T.J. The diagnostic validity of the Athens Insomnia Scale. J Psychosom Res 2003, 55:263-267.
25. Steiger A., Kimura M. Wake and sleep EEG provide biomarkers in depression. J Psychiatr Res 2010, 44:242-252.
26. Szelenberger W. Guidelines for the treatment of insomnia. Sen. 2006, 6:A1-A10.
27. Trachsel L., Dijk D.J., Brunner D.P., Klene C., Borbely A.A. Effect of zopiclone and midazolam on sleep and EEG spectra in a phase-advanced sleep schedule. Neuropsychopharmacology 1990, 3:11-18.
28. Walsh J.K., Erman M., Erwin C.W., Jamieson A., Mahowald M., Regestein Q., et al. Subjective hypnotic efficacy of trazodone and zolpidem in DSM III-R primary insomnia. Hum Psychopharmacol Clin Exp 1998, 13:191-198.
29. Walsh J.K., Krystal A.D., Amato D.A., Rubens R., Caron J., Wessel T.C., et al. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep 2007, 30:959-968.
30. Warner M.D., Dorn M.R., Peabody C.A. Survey on the usefulness of trazodone in patients with PTSD with insomnia or nightmares. Pharmacopsychiatry 2001, 34:128-131.
31. Wiegand M.H. Antidepressants for the treatment of insomnia: a suitable approach?. Drugs 2008, 68:2411-2417.
32. Wilson S.J., Nutt D.J., Alford C., Argyropoulos S.V., Baldwin D.S., Bateson A., et al. British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders. J Psychopharmacol 2010, 24:1577-1601.
33. Zavesicka L., Brunovsky M., Horacek J., Matousek M., Sos P., Krajca V., et al. Trazodone improves the results of cognitive behaviour therapy of primary insomnia in non-depressed patients. Neuro Endocrinol Lett 2008, 29:895-901.